A Pivotal Phase 2 Trial of Ponatinib (AP24534) in Patients With Refractory Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia

Trial Profile

A Pivotal Phase 2 Trial of Ponatinib (AP24534) in Patients With Refractory Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Jul 2017

At a glance

  • Drugs Ponatinib (Primary)
  • Indications Acute lymphoblastic leukaemia; Chronic myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms PACE
  • Sponsors ARIAD Pharmaceuticals
  • Most Recent Events

    • 25 Jun 2017 Long-term 5 year results presented at the 22nd Congress of the European Haematology Association.
    • 06 Jun 2017 Results (n=267, data cut off: 3 Oct 2016) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 06 Jun 2017 5-year results in patients with Chronic phase-Chronic-myeloid-leukaemia (n=270), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top